true nature is a development stage company focused on consolidating businesses in the compound pharmacy industry that serve both the human and veterinary markets. starting in the southeast, the company intends to acquire compounders across the us that meet their criteria and present a complementary fit to the true nature platform. mission: to unlock the potential of the compounding pharmacy industry to improve human and animal health, serve unmet patient needs, elevate the dignity of skilled pharmacists, and build shareholder value through the delivery of quality, cost effective, and innovative healthcare products and pharmaceuticals to the world. vision: to become globally recognized for our best practices focused on driving quality, efficiency and sustainability in the compounding pharmaceutical industry, natural solutions for healthy living, and novel approaches for delivery of these solutions.
Company profile
Ticker
MITI
Exchange
Website
CEO
Lawrence Diamond
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BRAIN TREE INTERNATIONAL INC, True Nature Holding, Inc., Trunity Holdings, Inc.
SEC CIK
Corporate docs
Subsidiaries
MitescoNA, LLC • The Good Clinic, LLC ...
MITI stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
16 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Mitesco Announces Advisory Board Appointments
20 Mar 24
8-K
Mitesco Continues Key Initiatives, Updates
8 Mar 24
8-K
Entry into a Material Definitive Agreement
6 Mar 24
8-K
Other Events
20 Feb 24
8-K
Mitesco Provides Shareholder Update
16 Feb 24
10-Q
2023 Q3
Quarterly report
13 Feb 24
8-K
Entry into a Material Definitive Agreement
30 Jan 24
8-K
Entry into a Material Definitive Agreement
18 Jan 24
Latest ownership filings
4
Jordan Paul Balencic
16 Jan 24
4
Mack Rimmer Jr. Leath
16 Jan 24
4
John Gormer Jr. Mitchell
16 Jan 24
3
Mack Rimmer Jr. Leath
4 Jan 24
3
John Gormer Jr. Mitchell
2 Jan 24
3
Jordan Paul Balencic
2 Jan 24
4
Lawrence M. Diamond
20 Dec 23
3
Lonnie Allen Plunk
18 Jul 23
4
Lawrence M. Diamond
10 Jul 23
4
Lawrence M. Diamond
30 Jan 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 255.89 k | 255.89 k | 255.89 k | 255.89 k | 255.89 k | 255.89 k |
Cash burn (monthly) | (no burn) | (no burn) | 2.51 mm | 2.41 mm | 160.97 k | 138.76 k |
Cash used (since last report) | n/a | n/a | 24.65 mm | 23.65 mm | 1.58 mm | 1.36 mm |
Cash remaining | n/a | n/a | -24.40 mm | -23.39 mm | -1.32 mm | -1.10 mm |
Runway (months of cash) | n/a | n/a | -9.7 | -9.7 | -8.2 | -8.0 |
Institutional ownership, Q2 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Jan 24 | John Gormer Jr. Mitchell | Series X Preferred | Grant | Acquire A | No | No | 25 | 2,400 | 60.00 k | 2,400 |
16 Jan 24 | Mack Rimmer Jr. Leath | Series X Preferred | Grant | Acquire A | No | No | 25 | 2,400 | 60.00 k | 2,400 |
16 Jan 24 | Jordan Paul Balencic | Series X Preferred | Grant | Acquire A | No | No | 25 | 2,400 | 60.00 k | 2,400 |